Screening and Treating a Generation for Hepatitis C

Segment 8 - Future of Innovation and Treatment Costs
February 18, 2014 – 
In the concluding segment, Dr Fendrick asks the panel to provide closing remarks about the future of treating hepatitis C (HCV). Dr Afdal says he believes this is a moment in time where a revolution is taking place.
Segment 7 - Patient Cost Sharing and Medication Adherence
February 18, 2014 – 
Dr Fendrick says that while indication and utilization of major innovations should be widespread, there are still questions of who will pay for them. As mentioned, plan sponsors (employers) are only 1 option.
Segment 6 - Screening and Appropriate Diagnosing in Hepatitis Treatment
February 18, 2014 – 
Dr Fendrick urges the panel to discuss which tools involving benefit design are being put into place to make sure that only those patients who would benefit most from new drugs are receiving them.
Segment 5 - The Role of the Primary Care Physician and Hepatologist in Treatment Regimens
February 18, 2014 – 
The panelists continue to debate whether hepatitis C virus (HCV) treatment should be administered by primary care physicians (PCPs) or hepatologists.
Segment 4 - Considering the Costs of Hepatitis C Treatment
February 18, 2014 – 
While some patients and physicians are not aware of the costs of care, others are concerned about whether they can afford treatment options at all. Dr Miller describes some of the major steps to the incremental benefits and incremental costs incurred by new agents.
Segment 3 - Engaging Patients in Discussions About Treating Hepatitis C
February 18, 2014 – 
Despite the relatively inexpensive 1-time tests to screen for hepatitis C virus (HCV), Dr Fendrick and the panel explore the concerns that plan sponsors may have regarding the costs of new specialty drugs made to treat HCV.
Segment 2 - The Effects of Health Reform on Treatment of Hepatitis C
February 18, 2014 – 
In this clip, the panel discusses the implications of health reform on the treatment of hepatitis C virus (HCV), including what is needed to improve outcomes. This includes educating primary care physicians about how the Affordable Care Act requires health plans to pay for the costs of testing and screening for risk factors of HCV.
Segment 1 - Hepatitis C in the Healthcare Reform Era
February 18, 2014 – 
Dr Mark Fendrick, University of Michigan, co-editor-in-chief, AJMC, moderates a discussion with Dr David Winston, section head of gastroenterology & hepatology, Cigna HealthCare of Arizona; Dr Steven Miller, chief medical officer, Express Scripts; and Dr Nezam H. Afdhal, associate professor of medicine, Harvard School of Medicine, chief of hepatology, director of Liver Center, Beth Israel Deaconess Medical Center.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.